News:

Here we provide you with news articles, blogs and tweets on the key aspects of our bioinformatics and drug resistance work.

In this new section of the bioafrica.net website, we disseminate printed and online media coverage of our work and its application in everyday life.


News Latest News

MSF


Open letter on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa

MSF - 2012-04-11

BioAfrica & SATuRN Supports this Open Letter!

Open letter to the Medicines Control Council and Ministry of Health on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDRTB in South Africa.

Dear Professor Eagles, Ms. Hela and Honorable Dr. Motsoaledi,

We urge you to take action to expedite compassionate use access for bedaquiline (TMC207) for persons with drug-resistant strains of tuberculosis in South Africa. Access to improved medicines to treat extensively drug resistant tuberculosis (XDR-TB) and pre-XDR-TB[1] is essential given the enormous public health threat that the drug-resistant TB epidemic exemplifies.

As you know, drug-resistant TB is a serious problem in South Africa, and the few treatment options that exist are only efficacious for a few patients, have major toxicity issues and are often unavailable. Patients have died, and are dying, and will continue to die because current drugs are failing to cure XDR-TB save for in a select few patients. Bedaquiline is the first TB drug in a new class to have been developed in 60 years. We agree with experts from the medical field that bedaquiline should be provided to select patients, to whom it offers the opportunity to be cured when no other options exist.


Open letter on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa

Please
click link to read the Open letter on urgent need for compassionate use of bedaquiline for XDR-TB and pre-XDR-TB in South Africa.

Links:

http://www.msf.org.za/publication/open-letter-medicines-control-council-south-africa

15 minutes, All news...

Why KRISP? KRISP challenges the status quo to create a scientific environment in South Africa that drives innovations & reverses the brain drain.
From Why KRISP?, date: 2017-12-31

Even with easy access to ARVs, only one in three HIV-positive people will seek them
From KRISP News, date: 2017-12-05

South Africans with HIV miss out on the benefits of early treatment due to a fear of stigma
From KRISP News, date: 2017-12-02
15 minutes, All news...


Page design updated by Tulio de Oliveira, 2015